TipRanks
Chemical Works of Gedeon Richter Plc (DE:RIG2)
FRANKFURT:RIG2

Chemical Works of Gedeon Richter (RIG2) Price & Analysis

7 Followers

RIG2 Stock Chart & Stats

€36.64
-€0.66(-2.00%)
At close: 4:00 PM EDT
€36.64
-€0.66(-2.00%)

Chemical Works of Gedeon Richter News

RIG2 FAQ

What was Chemical Works of Gedeon Richter Plc’s price range in the past 12 months?
Chemical Works of Gedeon Richter Plc lowest stock price was €24.60 and its highest was €37.02 in the past 12 months.
    What is Chemical Works of Gedeon Richter Plc’s market cap?
    Chemical Works of Gedeon Richter Plc’s market cap is €6.44B.
      When is Chemical Works of Gedeon Richter Plc’s upcoming earnings report date?
      Chemical Works of Gedeon Richter Plc’s upcoming earnings report date is Nov 10, 2026 which is in 9 days.
        How were Chemical Works of Gedeon Richter Plc’s earnings last quarter?
        Chemical Works of Gedeon Richter Plc released its earnings results on Aug 07, 2026. The company reported €1.54 earnings per share for the quarter.
          Is Chemical Works of Gedeon Richter Plc overvalued?
          According to Wall Street analysts Chemical Works of Gedeon Richter Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Chemical Works of Gedeon Richter Plc pay dividends?
            Chemical Works of Gedeon Richter Plc does not currently pay dividends.
            What is Chemical Works of Gedeon Richter Plc’s EPS estimate?
            Chemical Works of Gedeon Richter Plc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Chemical Works of Gedeon Richter Plc have?
            Chemical Works of Gedeon Richter Plc has 186,374,860 shares outstanding.
              What happened to Chemical Works of Gedeon Richter Plc’s price movement after its last earnings report?
              Chemical Works of Gedeon Richter Plc reported an EPS of €1.54 in its last earnings report. Following the earnings report the stock price went down -0.77%.
                Which hedge fund is a major shareholder of Chemical Works of Gedeon Richter Plc?
                Currently, no hedge funds are holding shares in DE:RIG2
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Chemical Works of Gedeon Richter Plc

                  Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. The firm focuses on central nervous system, women's healthcare, cardiovascular, and OTC products. It operates through the following segments: Neuropsychiatry (CNS), General Medicines (GM), Women’s Healthcare (WHC), Biotechnology (BIO), and Pharma Other. The CNS segment focuses on building a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry. The GM segment includes a traditional and generic portfolio in various therapeutic areas in the Central and Eastern European regions. The WHC segment provides pharmaceutical products for European women. The BIO segment is involved in its biotechnology platform to develop and manufacture biosimilar drugs for global markets. The Pharma Other segment relates to the remaining wholesale and retail business of the Group and all other activities. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.

                  Chemical Works of Gedeon Richter (RIG2) Earnings & Revenues

                  RIG2 Company Deck

                  RIG2 Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The earnings call presented strong underlying operational progress: solid constant-currency revenue growth (8.7%), a significant 21% rise in Clean EBIT on a constant-currency basis, robust biotech and CNS performance, record free cash flow, and measurable cost/ESG benefits from API consolidation. However, reported results were meaningfully impacted by FX losses (notably >HUF 32bn in Q2), a weaker General Medicines performance affected by timing and market factors, one-off impairments in Biotech, and restructuring costs. On balance, the operational wins, upgraded Clean EBIT guidance, cash generation and pipeline progress outweigh the transitory negatives driven largely by FX and one-off items, supporting a constructive outlook.View all DE:RIG2 earnings summaries

                  RIG2 Stock 12 Month Forecast

                  Average Price Target

                  €40.20
                  ▲(9.71% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"€22","41":"€41","26.75":"€26.8","31.5":"€31.5","36.25":"€36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.19833818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€40.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.19833818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€40.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.19833818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€40.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,26.75,31.5,36.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.96,34.43987216769231,34.919744335384614,35.39961650307692,35.879488670769234,36.35936083846154,36.83923300615385,37.319105173846154,37.79897734153846,38.27884950923077,38.758721676923074,39.23859384461539,39.718466012307694,{"y":40.19833818,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.96,34.43987216769231,34.919744335384614,35.39961650307692,35.879488670769234,36.35936083846154,36.83923300615385,37.319105173846154,37.79897734153846,38.27884950923077,38.758721676923074,39.23859384461539,39.718466012307694,{"y":40.19833818,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.96,34.43987216769231,34.919744335384614,35.39961650307692,35.879488670769234,36.35936083846154,36.83923300615385,37.319105173846154,37.79897734153846,38.27884950923077,38.758721676923074,39.23859384461539,39.718466012307694,{"y":40.19833818,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.739,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.611,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.923,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.644,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.281,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.975,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":28.95,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.338,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":33.352,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.12,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.28,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Chemical Works of Gedeon Richter
                  ―
                  ―
                  Dr Reddy's Laboratories
                  ―
                  ―
                  Teva
                  ―
                  ―
                  Perrigo Company
                  ―
                  ―
                  AstraZeneca
                  ―
                  ―
                  Pfizer
                  ―
                  ―
                  GlaxoSmithKline
                  ―
                  ―
                  Popular Stocks